Tempest Therapeutics CFO Constance Ames Resigns; Co. Names Stephanie Horn-Warnock CFO, Treasurer, And Corporate Secretary, Effective Immediately.
Tempest Therapeutics Inc TPST
$0.37
▲ +3.54%
(+$0.01)
📉 Near 52W Low
Open
$0.40
Prev Close
$0.36
Day Range
$0.34 – $0.40
52W Range
$0.36 – $10.33
Market Cap
$7.23M
Beta
-1.32
EPS (TTM)
$-4.49
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2012-10-04 |
| Shares Out. | 20,000,000 |
| Website | tempesttx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 4 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$5.2M |
| Free Cash Flow | -$20.7M |
| Total Assets | $9.6M |
| Total Liabilities | $10.7M |
| Equity | -$1.1M |
About Tempest Therapeutics Inc
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
Tempest Therapeutics Inc is a publicly traded company under the ticker symbol TPST on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-11-01)